房颤患者抗凝后卒中复发残余风险的系统综述与荟萃分析
该系统综述与荟萃分析纳入23项研究、78 733例房颤合并既往缺血性卒中患者,中位抗凝使用比例92%。汇总复发缺血性卒中发生率为每年3.75%(95%CI 3.17%-4.33%),非干预观察队列为每年4.20%高于随机临床试验的每年2.26%(交互P<.001)。抗凝后仍发生卒中亚组复发缺血性卒中风险为每年7.20%。
要点
- 房颤合并既往缺血性卒中患者抗凝后复发缺血性卒中汇总发生率每年3.75%。
- 非干预观察队列复发风险每年4.20%高于随机临床试验每年2.26%(交互P<.001)。
- 抗凝后仍发生卒中亚组复发缺血性卒中风险每年7.20%,颅内出血每年1.40%。
核心结论
- 即使采用现代预防治疗,房颤相关卒中后的残余复发风险仍较高,估计5年时约六分之一患者发生复发缺血性卒中。
- 原文指出亟需加深对复发生物学过程的理解、改进风险分层并开发新的二级预防策略。
研究设计与样本
- 系统综述与荟萃分析,检索Ovid MEDLINE(自1946年1月)和Embase(自1970年1月)至2025年1月。
- 纳入报告既往缺血性卒中合并房颤患者复发卒中发生率且随访≥1年的研究,共23项研究、78 733例患者、140 307随访年。
- 由3名评价者独立筛选摘要和全文,2名提取数据并由第3名独立核实,采用随机效应模型汇总发生率,使用Quality In Prognosis Studies工具评估研究质量。
主要发现
- 研究中位抗凝使用比例为92%。
- 汇总复发缺血性卒中发生率为每年3.75%(95%CI 3.17%-4.33%)。
- 非干预观察队列复发缺血性卒中风险为每年4.20%(95%CI 3.41%-4.99%),高于随机临床试验的每年2.26%(95%CI 1.96%-2.57%),交互P<.001。
- 任何复发卒中(缺血性卒中或颅内出血)风险为每年4.88%(95%CI 3.87%-5.90%),颅内出血风险为每年0.58%(95%CI 0.43%-0.73%)。
- 抗凝后仍发生卒中亚组中,复发缺血性卒中风险为每年7.20%(95%CI 5.05%-9.34%),任何卒中为每年8.96%(95%CI 8.25%-9.67%),颅内出血为每年1.40%(95%CI 0.40%-2.40%)。
关键数值与推荐
- 主要结局为复发缺血性卒中,次要结局为任何复发卒中(缺血性卒中或颅内出血)和随访期间颅内出血。
- 复发缺血性卒中汇总发生率每年3.75%(95%CI 3.17%-4.33%)。
- 任何复发卒中汇总发生率每年4.88%(95%CI 3.87%-5.90%),颅内出血每年0.58%(95%CI 0.43%-0.73%)。
- 抗凝后仍发生卒中亚组:缺血性卒中每年7.20%(95%CI 5.05%-9.34%),任何卒中每年8.96%(95%CI 8.25%-9.67%),颅内出血每年1.40%(95%CI 0.40%-2.40%)。
临床怎么用
- 原文未报告临床实践推荐。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Atrial fibrillation (AF) is a leading cause of stroke, and oral anticoagulants (OAC) reduce this risk. However, there are limited data on the residual risk of recurrent stroke in patients with AF. OBJECTIVE: To determine the recurrent stroke risk in patients with AF by performing a systematic review and meta-analysis. DATA SOURCES: Eligible studies were identified by searching Ovid MEDLINE and Embase from inception (Ovid: January 1946; Embase: January 1970) until January 2025. STUDY SELECTION: Eligible studies enrolled patients with prior ischemic stroke and AF, reported information on incidence of recurrent stroke, and had follow-up data for 1 or more years. Three reviewers independently screened abstracts and performed full-text reviews. DATA EXTRACTION AND SYNTHESIS: Data extraction was performed by 2 reviewers and independently verified by a third. Incidence rates were pooled using random-effects meta-analysis. Analysis was repeated in patients whose qualifying event occurred despite OAC. Study quality was assessed using the Quality In Prognosis Studies tool. MAIN OUTCOMES AND MEASURES: The primary outcome was recurrent ischemic stroke. The secondary outcomes were any recurrent stroke (ischemic stroke or intra-cerebral hemorrhage [ICH]) and ICH during follow-up. RESULTS: A total of 23 studies were identified, which included 78 733 patients and 140 307 years of follow-up. The median proportion of OAC use across studies was 92%. The pooled incidence of recurrent ischemic stroke was 3.75% per year (95% CI, 3.17%-4.33%). The risk was higher in noninterventional observational cohorts (4.20% per year; 95% CI, 3.41%-4.99%) compared with randomized clinical trials (2.26% per year; 95% CI, 1.96%-2.57%) (P value for interaction <.001). The risk of any recurrent stroke was 4.88% per year (95% CI, 3.87%-5.90%), and the risk of ICH was 0.58% per year (95% CI, 0.43%-0.73%). In patients with stroke despite OAC, the risk was 7.20% per year (95% CI, 5.05%-9.34%) for ischemic stroke, 8.96% per year (95% CI, 8.25%-9.67%) for any stroke, and 1.40% per year (95% CI, 0.40%-2.40%) for ICH. CONCLUSIONS AND RELEVANCE: In this systematic review and meta-analysis, even with modern prevention therapy, the residual recurrence risk after AF-related stroke is high, with an estimated 1 in 6 patients experiencing a recurrent ischemic stroke at 5 years. These data demonstrate an urgent need to improve our understanding of the biological processes responsible for recurrence, improve risk stratification, and develop new secondary prevention strategies after AF-related stroke.
引用
- McCabe JJ, Cheung Y, Foley M, et al. Residual Risk of Recurrent Stroke Despite Anticoagulation in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. JAMA Neurol. 2025. PMID: 40394992. doi:10.1001/jamaneurol.2025.1337
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。